Biogen has halved the price of its Alzheimer’s drug Aduhelm after sales fell short of expectations because insurers have been reluctant to pay for the treatment.
由于保险公司不愿为治疗阿兹海默症的药物Aduhelm支付费用，百健已将这款销售低于预期的药物价格砍半。
您已阅读9%（212字），剩余91%（2083字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。